Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists

Journal of Medicinal Chemistry

Volumn 45, Issue 21, 2002, Pages 4737-4747

  Rivier, J ^a   Gulyas, J ^a   Kirby, D ^a   Low, W ^a   Perrin, M H ^a   Kunitake, K ^a   DiGruccio, M ^a   Vaughan, J ^a   Reubi, J C ^b   Waser, B ^b   Koerber, S C ^a   Martinez, V ^c   Wang, L ^d   Tache Y ^d   Vale, W ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSIDAD CEU CARDENAL HERRERA   (Spain)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASTRESSIN; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; HELIX LOOP HELIX PROTEIN; LONG ACTING DRUG; SAUVAGINE; UROCORTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CIRCULAR DICHROISM; CONTROLLED STUDY; CORTICOTROPIN RELEASE; DRUG ANTAGONISM; DRUG CONFORMATION; DRUG POTENCY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; PHYSICAL CHEMISTRY; RAT; STOMACH EMPTYING; STRUCTURE ACTIVITY RELATION;

ANIMALS; AUTORADIOGRAPHY; BINDING, COMPETITIVE; BRAIN; CHO CELLS; CORTICOTROPIN-RELEASING HORMONE; CRICETINAE; EATING; GASTRIC EMPTYING; MALE; MICE; MICE, INBRED C57BL; ORGAN SPECIFICITY; PEPTIDE FRAGMENTS; PEPTIDES, CYCLIC; RADIOLIGAND ASSAY; RATS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037057557     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0202122     Document Type: Article

References (46)

1. Fisher, L. A.; Rivier, C.; Rivier, J.; Brown, M. R. Differential antagonist activity of α-helical CRF(9-41) in three bioassay systems. Endocrinology 1991, 129, 1312-1316.
2. Perrin, M. H.; Sutton, S. W.; Cervini, L.; Rivier, J. E.; Vale, W. W. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of CRF receptors. J. Pharmacol. Exp. Ther. 1999, 288, 729-734.
3. Koerber, S. C.; Gulyas, J.; Lahrichi, S. L.; Corrigan, A.; Craig, A. G.; Rivier, C.; Vale, W. W.; Rivier, J. Constrained corticotropin releasing factor (CRF) agonists and antagonists with i-(i+3) GluXaa-DXbb-Lys bridges. J. Med. Chem. 1998, 41, 5002-5011.
4. Rühmann, A.; Bonk, I.; Lin, C. R.; Rosenfeld, M. G.; Spiess, J. Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): Development of CRFR2β-selective antisauvagine-30. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 15264-15269.
5. Chen, R.; Lewis, K. A.; Perrin, M. H.; Vale, W. W. Expression cloning of a human corticotropin releasing factor (CRF) receptor. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 8967-8971.
6. Liaw, C. W.; Lovenberg, T. W.; Barry, G.; Oltersdorf, T.; Grigoriadis, D. E.; DeSouza, E. B. Cloning and characterization of the human corticotropin-releasing factor-2 receptor complementary deoxyribonucleic acid. Endocrinology 1996, 137, 72-77.
7. Perrin, M.; Donaldson, C.; Chen, R.; Blount, A.; Berggren, T.; Bilezikjian, L.; Sawchenko, P.; Vale, W. Identification of a second CRF receptor gene and characterization of a cDNA expressed in heart. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 2969-2973.
8. Reyes, T. M.; Lewis, K.; Perrin, M. H.; Kunitake, K. S.; Vaughan, J.; Arias, C. A.; Hogenesch, J. B.; Gulyas, J.; Rivier, J.; Vale, W. W.; Sawchenko, P. E. Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 2843-2848.
9. Lewis, K.; Li, C.; Perrin, M. H.; Blount, A.; Kunitake, K.; Donaldson, C.; Vaughan, J.; Reyes, T. M.; Gulyas, J.; Fischer, W.; Bilezikjian, L.; Rivier, J.; Sawchenko, P. E.; Vale, W. W. Identification of Urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 7570-7575.
10. Hsu, S. Y.; Hsueh, A. J. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat. Med. 2001, 7, 605-611.
11. Rivier, J.; Rivier, C.; Vale, W. Synthetic competitive antagonists of corticotropin releasing factor: Effect on ACTH secretion in the rat. Science 1984, 224, 889-891.
12. Muglia, L.; Jacobson, L.; Dikkes, P.; Majzoub, J. A. Corticotropin-releasing hormone deficiency reveals major fetal but not adult glucocorticoid need. Nature 1995, 373, 427-432.
13. Weninger, S. C.; Dunn, A. J.; Muglia, L. J.; Dikkes, P.; Miczek, K. A.; Swiergiel, A. H.; Berridge, C. W.; Majzoub, J. A. Stress-induced behaviors require the corticotropin-releasing hormone (CRH) receptor, but not CRH. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 8283-8288.
14. Hernandez, J.-F.; Kornreich, W.; Rivier, C.; Miranda, A.; Yamamoto, G.; Andrews, J.; Taché, Y.; Vale, W. W.; Rivier, J. E. Synthesis and relative potencies of new constrained CRF antagonists. J. Med. Chem. 1993, 36, 2860-2867.
15. Miranda, A.; Koerber, S. C.; Gulyas, J.; Lahrichi, S.; Craig, A. G.; Corrigan, A.; Hagler, A.; Rivier, C.; Vale, W. W.; Rivier, J. E. Conformationally restricted competitive antagonists of human/rat corticotropin-releasing factor. J. Med. Chem. 1994, 37, 1450-1459.
16. Gulyas, J.; Rivier, C.; Perrin, M.; Koerber, S. C.; Sutton, S.; Corrigan, A.; Lahrichi, S. L.; Craig, A. G.; Vale, W. W.; Rivier, J. Potent, structurally constrained agonists and competitive antagonists of corticotropin releasing factor (CRF). Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 10575-10579.
17. Vaughan, J. M.; Donaldson, C.; Bittencourt, J.; Perrin, M. H.; Lewis, K.; Sutton, S.; Chan, R.; Turnbull, A.; Lovejoy, D.; Rivier, C.; Rivier, J.; Sawchenko, P. E.; Vale, W. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995, 378, 287-292.
18. 2β receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology 1995, 136, 4139-4142.
19. Ardati, A.; Goetschy, V.; Gottowick, J.; Henriot, S.; Valdenaire, O.; Deuschle, U.; Kilpatrick, G. J. Human CRF2 alpha and beta splice variants: pharmacological characterization using radioligand binding and a luciferase gene expression assay. Neuropharmacology 1999, 38, 441-448.
20. Brar, B. K.; Jonassen, A. K.; Stephanou, A.; Santilli, G.; Railson, J.; Knight, R. A.; Yellon, D. M.; Latchman, D. S. Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway. J. Biol. Chem. 2000, 275, 8508-8514.
21. Singh, L. K.; Boucher, W.; Pang, X.; Letourneau, R.; Seretakis, D.; Green, M.; Theoharides, T. C. Potent mast cell degranulation and vascular permeability triggered by urocortin through activation of corticotropin-releasing hormone receptors. J. Pharmacol. Exp. Ther. 1999, 288, 1349-1356.
22. Nozu, T.; Martínez, V.; Rivier, J.; Taché, Y. Peripheral urocortin delays gastric emptying: role of CRF 2 receptors. Am. J. Physiol.-Gastrointest. Liver Physiol. 1999, 39, G867-G874.
23. McCarthy, J. R.; Heinrichs, S. C.; Grigoriadis, D. E. Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications. Curr. Pharm. Des. 1999, 5, 289-315.
24. Asakawa, A.; Inui, A.; Ueno, N.; Makino, S.; Fujino, M. A.; Kasuga, M. Urocortin reduces food intake and gastric emptying in lean and ob/ob obese mice. Gastroenterology 1999, 116, 1287-1292.
25. Wang, L. X.; Martfnez, V.; Rivier, J. E.; Taché, Y. Peripheral urocortin inhibits gastric emptying and food intake in mice: differential role of CRF receptor 2. Am. J. Physiol.-Regul. Integ. Comput. Physiol. 2001, 281, R1401-R1410.
26. Rivier, J.; Lahrichi, S. L.; Gulyas, J.; Erchegyi, J.; Koerber, S. C.; Craig, A. G.; Corrigan, A.; Rivier, C.; Vale, W. Minimal-size, constrained corticotropin releasing factor agonists with i-(i+3) Glu-Lys and Lys-Glu bridges. J. Med. Chem. 1998, 41, 2614-2620.
27. Miranda, A.; Lahrichi, S. L.; Gulyas, J.; Koerber, S. C.; Craig, A. G.; Corrigan, A.; Rivier, C.; Vale, W. W.; Rivier, J. E. Constrained corticotropin releasing factor (CRF) antagonists with i-(i+3) Glu - Lys bridges. J. Med. Chem. 1997, 40, 3651-3658.
28. Miranda, A.; Lahrichi, S.; Gulyas, J.; Rivier, C.; Koerber, S.; Miller, C.; Corrigan, A.; Sutton, S.; Craig, A. G.; Vale, W.; Rivier, J. Competitive antagonists of the corticotropin releasing factor (CRF) scanned with an i-(i+3) Glu Lys Bridge. Fifteenth American Peptide Symposium, Nashville, TN, 1997; pp 2-164.
29. Rivier, J.; Rivier, C.; Galyean, R.; Miranda, A.; Miller, C.; Craig, A. G.; Yamamoto, G.; Brown, M.; Vale, W. Single point D-substituted corticotropin releasing factor analogues: Effects on potency and physicochemical characteristics. J. Med. Chem. 1993, 36, 2851-2859.
30. Rivier, J.; Spiess, J.; Vale, W. Characterization of rat hypothalamic corticotropin-releasing factor. Proc. Natl. Acad. Sci. U.S.A. 1983, 80, 4851-4855.
31. Rivier, J. E.; Kirby, D. A.; Lahrichi, S. L.; Corrigan, A.; Vale, W. W.; Rivier, C. L. Constrained corticotropin releasing factor (CRF) antagonists (Astressin analogues) with long duration of action in the rat. J. Med. Chem. 1999, 42, 3175-3182.
32. Böhm, G.; Muhr, R.; Jaenicke, R. Quantitative analysis of protein far UV circular dichroism spectra by neural networks. Protein Eng. 1992, 5, 191-195.
33. 2-mediated action on gastric transit in rats. Am. J. Physiol.-Gastrointest. Liver Physiol. 2002, 282, G34-G40.
34. Martínez, V.; Wang, L.; Rivier, J. E.; Vale, W.; Taché, Y. Differential actions of peripheral corticotropin-releasing factor (CRF), urocortin II, and urocortin III on gastric emptying and colonic transit in mice: Role of CRF receptor subtypes 1 and 2. J. Pharmacol. Exp. Ther. 2002, 301, 611-617.
35. Felix, A. M.; Heimer, E. P.; Wang, C. T.; Lambros, T. J.; Fournier, A.; Mowles, T. F.; Maines, S.; Campbell, R. M.; Wegrzynski, B. B.; Toome, V.; Fry, D.; Madison, V. S. Synthesis, biological activity and conformational analysis of cyclic GRF analogues. Int. J. Pept. Prot. Res. 1988, 32, 441-454.
36. Felix, A. M.; Wang, C.-T.; Heimer, E. P.; Fournier, A. Applications of BOP reagent in solid-phase synthesis. II. Solid-phase side-chain to side-chain cyclizations using BOP reagent. Int. J. Pept. Prot. Res. 1988, 31, 231-238.
37. Hoeger, C. A.; Galyean, R. F.; Boublik, J.; McClintock, R. A.; Rivier, J. E. Preparative reversed phase high performance liquid chromatography. II. Effects of buffer pH on the purification of synthetic peptides. Biochromatography 1987, 2, 134-142.
38. Rivier, J. Use of trialkylammonium phosphate (TAAP) buffers in reverse phase HPLC for high resolution and high recovery of peptides and proteins. J. Liq. Chromatogr. 1978, 1, 343-367.
39. Vale, W.; Vaughan, J.; Yamamoto, G.; Bruhn, T.; Douglas, C.; Dalton, D.; Rivier, C.; Rivier, J. Assay of corticotropin releasing factor. Methods in Enzymology: Neuroendocrine Peptides; Academic Press: New York, 1983; pp 565-577.
40. Perrin, M. H.; Donaldson, C.; Chen, R.; Blount, A.; Berggren, T.; Bilezikjian, L.; Sawchenko, P.; Vale, W. W. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 2969-2973.
41. Sutton, S. W.; Behan, D. P.; Lahrichi, S.; Kaiser, R.; Corrigan, A.; Lowry, P.; Potter, E.; Perrin, M.; Rivier, J.; Vale, W. W. Ligand requirements of the human corticotropin releasing factor binding protein. Endocrinology 1995, 136, 1097-1102.
42. Perrin, M. H.; Haas, Y.; Rivier, J. E.; Vale, W. W. Corticotropin releasing factor binding to the anterior pituitary receptor is modulated by divalent cations and guanyl nucleotides. Endocrinology 1986, 118, 1171-1179.
43. DeSouza, E. B.; Kuhar, M. J. Corticotropin-releasing factor receptors in the pituitary gland and central nervous system: methods and overview. Methods Enzymol. 1986, 124, 560-590.
44. Reubi, J. C.; Kvols, L. K.; Waser, B.; Nagorney, D.; Heitz, P. U.; Charboneau, J. W.; Reading, C. C.; Moertel, C. Detection of somatosatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res. 1990, 50, 5969-5977.
45. Barrachina, M. D.; Martinez, V.; Wei, J. Y.; Taché, Y. Lept-ininduced decrease in food intake is not associated with changes in gastric emptying in lean mice. Am. J. Physiol. 1997, 272, R1007-R1011.
46. Barrachina, M. D.; Martinez, V.; Wang, L.; Wei, J. Y.; Taché, Y. Synergistic interaction between leptin and cholecystokinin to reduce short-term food intake in lean mice. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 10455-10460.